Dapagliflozin was well tolerated among patients hospitalized with COVID-19

Among patients hospitalized with COVID-19, dapagliflozin was well tolerated and did not increase risk of AKI in patients, according to data published in the Clinical Journal of the American Society of Nephrology.
Further, dapagliflozin was well tolerated among patients with an eGFR below 60 mL/minute per 1.73² and among those with an eGFR above 60 mL/minute per 1.73².
“The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial was designed to assess the efficacy and safety of the SGLT2 inhibitor dapagliflozin in 1,250 patients with cardiometabolic risk

Among patients hospitalized with COVID-19, dapagliflozin was well tolerated and did not increase risk of AKI in patients, according to data published in the Clinical Journal of the American Society of Nephrology.
Further, dapagliflozin was well tolerated among patients with an eGFR below 60 mL/minute per 1.73² and among those with an eGFR above 60 mL/minute per 1.73².
“The Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial was designed to assess the efficacy and safety of the SGLT2 inhibitor dapagliflozin in 1,250 patients with cardiometabolic risk